Pipeline
Last Updated Date: April 28, 2022
The impossible is simply what hasn’t been achieved yet. Gilead’s research and development program is focused on what’s next. We discover, identify and evaluate investigational compounds that show potential to advance the treatment of life-threatening diseases.
Clinical Stage Programs1
Potential clinical stage opt-in assets
1 Program count does not include potential partner opt-in programs or publicly announced planned programs.
On this page
Viral Diseases
Inflammatory Diseases

The safety and efficacy of the following investigational compounds or investigational uses of marketed products have not been established. These uses have not been approved by the U.S. Food and Drug Administration or other regulatory authorities unless otherwise noted.
-
Oral CoV prodrug (GS-5245)
COVID-19
PHASE 1
-
Lenacapavir capsid inhibitor (CAPELLA)1,2
Long acting HIV treatment for heavily treatment experienced people living with HIV
FILED NDA/MAA
-
Lenacapavir capsid inhibitor (PURPOSE 1 & 2)1
HIV PrEP
PHASE 3
-
Lenacapavir capsid inhibitor (GS-6207)1,3
Long acting HIV treatment for virologically suppressed people living with HIV
PHASE 2
-
Lenacapavir/islatravir oral combination1,4
Long acting HIV treatment for virologically suppressed people living with HIV
PHASE 2
-
bNAb combination (GS-5423, GS-2872)5
HIV cure
PHASE 2
-
Lefitolimod TLR-9 agonist (GS-1703)5
HIV cure
PHASE 2
-
Vesatolimod TLR-7 agonist (GS-9620)5
HIV cure
PHASE 2
-
Therapeutic vaccines6
HIV cure
PHASE 1
-
Lenacapavir / bNAb combination
Long acting HIV treatment for virologically suppressed people living with HIV
PHASE 1
-
Lenacapavir / bictegravir oral combination
Long acting HIV treatment for virologically suppressed people living with HIV
PHASE 1
-
Long acting bictegravir (GS-9883)
Long acting HIV treatment
PHASE 1
HBV and HDV
-
Hepcludex® (bulevirtide)7,8
HDV
FILED BLA
-
Hepcludex® (bulevirtide)
HDV
PHASE 2
-
Selgantolimod TLR-8 agonist (GS-9688)
HBV cure
PHASE 2
1 Program timeline pending resolution of FDA Complete Response Letter and clinical hold on studies evaluating injectable lenacapavir, as well as a clinical hold on studies evaluating islatravir.
2 Breakthrough therapy designation.
3 Phase 2 study being conducted in treatment naïve patients to support virologically suppressed indication.
4 Subject to Gilead and Merck co-development and co-commercialization agreement.
5 Non-Gilead sponsored trial(s) ongoing.
6 Clinical collaboration with Gritstone.
7 Conditionally approved by the European Medicines Agency (EMA) for the treatment of chronic HDV infection in adults with compensated liver disease in July 2020.
8 Breakthrough and PRIME designations.
bNAb – Broadly neutralizing antibody.
TLR – Toll-like receptor.
Inflammatory Diseases
-
Filgotinib JAK-1 inhibitor (GS-6034)1
Crohn's disease
PHASE 3
-
TPL2 inhibitor (GS-5290)
Inflammatory bowel disease
PHASE 1
-
IRAK4 inhibitor (GS-5718)
Inflammatory bowel disease
PHASE 1
-
IRAK4 inhibitor (GS-5718)
Rheumatoid arthritis
PHASE 1
-
IRAK4 inhibitor (GS-5718)2
Lupus
PHASE 1
-
α4β7 inhibitor (GS-1427)
Inflammatory bowel disease
PHASE 1
Fibrotic Diseases
-
Cilofexor FXR agonist (PRIMIS)
Primary sclerosing cholangitis
PHASE 3
-
Cilofexor / firsocostat / semaglutide combination3
Nonalcoholic steatohepatitis
PHASE 2
Potential Opt-in Programs
Galapagos
Inflammatory and fibrotic diseases
7 clinical stage programs
1 In collaboration with Galapagos.
2 Screening/enrollment paused pending evaluation of preliminary preclinical findings.
3 Clinical collaboration with Novo Nordisk.
-
Sacituzumab govitecan-hziy (TROPiCS-02)
Hormone receptor positive, human epidermal growth factor receptor 2 negative, metastatic breast cancer
PHASE 3
-
Sacituzumab govitecan-hziy (EVOKE-01)
2-3L non small cell lung cancer
PHASE 3
-
Sacituzumab govitecan-hziy (ASCENT-03)1,2
1L metastatic triple-negative breast cancer (PD-L1+)
PHASE 3
-
Sacituzumab govitecan-hziy (ASCENT-04)1,2
1L metastatic triple-negative breast cancer (PD-L1-)
PHASE 3
-
Sacituzumab govitecan-hziy (EVOKE-03)1,2
1L non small cell lung cancer
PHASE 3
-
Magrolimab anti-CD47 (ENHANCE)3,4
1L higher risk myelodysplastic syndrome
PHASE 3
-
Magrolimab anti-CD47 (ENHANCE-2)4
1L acute myeloid leukemia
PHASE 3
-
Magrolimab anti-CD47 (ENHANCE-3)1
1L unfit acute myeloid leukemia
PHASE 3
-
Domvanalimab + zimberelimab vs. zimberelimab vs. chemo (ARC-10)5
1L non small cell lung cancer
PHASE 3
-
Durvalumab ± domvanalimab
(PACIFIC-8)6Stage 3 non small cell lung cancer
PHASE 3
-
Domvanalimab + zimberelimab + chemo vs. pembrolizumab + chemo (STAR-121)1,5
1L non small cell lung cancer
PHASE 3
-
Sacituzumab govitecan-hziy (GS-0132)1
1L non small cell lung cancer
PHASE 2
-
Sacituzumab govitecan-hziy (GS-0132)
1L metastatic urothelial carcinoma
PHASE 2
-
Sacituzumab govitecan-hziy (GS-0132)
Basket (Solid tumors)
PHASE 2
-
Magrolimab anti-CD47 (GS-4721)
Head and neck squamous cell carcinoma
PHASE 2
-
Magrolimab anti-CD47 (GS-4721)
Solid tumors
PHASE 2
-
Magrolimab anti-CD47 (GS-4721)7
Multiple myeloma
PHASE 2
-
Magrolimab anti-CD47 (GS-4721)
Triple-negative breast cancer
PHASE 2
-
Magrolimab anti-CD47 (GS-4721)1
Metastatic colorectal cancer
PHASE 2
-
Zimberelimab vs. zimberelimab + domvanalimab vs. zimberelimab + domvanalimab + etrumadenant (ARC-7)5
Non small cell lung cancer
PHASE 2
-
Quemliclustat + zimberelimab + gemcitabine/nab-paclitaxel (ARC-8)5
Metastatic pancreatic ductal adenocarcinoma
PHASE 2
-
Etrumadenant combinations (ARC-9)5
Metastatic colorectal cancer
PHASE 2
-
Domvanalimab + zimberelimab ± chemo (ARC-21)1,5
1-2L upper GI cancer
PHASE 2
-
Etrumadenant combinations (ARC-6)5
Metastatic castrate-resistant prostate cancer
PHASE 1b/2
-
Magrolimab anti-CD47 (GS-4721)7
Diffuse large B-cell lymphoma
PHASE 1b/2
-
AB308 + zimberelimab (ARC-12)5
Advanced cancers
PHASE 1b
-
Flt3R agonist (GS-3583)
Advanced cancers
PHASE 1b
-
Anti-c-KIT (GS-0174)
Transplant conditioning regimen
PHASE 1a
-
CCR8 (GS-1811)
Advanced cancers
PHASE 1a
-
MCL1 inhibitor (GS-9716)
Advanced cancers
PHASE 1a
-
Yescarta® (ZUMA-22)1
2L+ high-risk follicular lymphoma
PHASE 3
-
Yescarta® (ZUMA-23)1
1L high-risk large B-cell lymphoma
PHASE 3
-
Yescarta® (axi-cel)1
2L large B-cell lymphoma Outpatient
PHASE 2
-
Yescarta® (axi-cel)
1L large B-cell lymphoma
PHASE 2
-
Brexu-cel
Pediatric acute lymphocytic leukemia
PHASE 2 Pivotal
-
Brexu-cel1
Basket (rare B-cell malignancies)
PHASE 2
-
KITE-222 (CLL-1)
Relapsed/refractory acute myeloid leukemia
PHASE 1
-
KITE-363 (CD19/20 bicistronic)
3L+ large B-cell lymphoma
PHASE 1
Potential Opt-in Programs
Pionyr
Solid tumors
2 clinical stage programs
Agenus
Solid tumors
1 clinical stage program
Arcus
Advanced cancers
1 clinical stage program
Tizona
Advanced cancers
1 clinical stage program
1 Publicly announced planned program (non-exhaustive).
2 In collaboration with Merck.
3 Breakthrough and PRIME designations and Promising Innovative Medicine from MHRA.
4 Additional MDS and AML cohorts within other ongoing Phase 1b study.
5 In collaboration with Arcus Biosciences.
6 In collaboration with Arcus Biosciences and AstraZeneca.
7 Program timeline pending resolution of FDA clinical hold on studies evaluating magrolimab for DLBCL and MM.
Axi-cel – Axicabtagene ciloleucel.
Brexu-cel – Brexucabtagene autoleucel.
Some of the content on this page is not intended for users outside the United States.